Zimmer Biomet (ZBH) Competitors $99.44 +1.07 (+1.09%) Closing price 10/15/2025 03:59 PM EasternExtended Trading$98.99 -0.45 (-0.45%) As of 10/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ZBH vs. PEN, SYK, GEHC, PHG, SNN, SOLV, STVN, IRTC, BLCO, and GKOSShould you be buying Zimmer Biomet stock or one of its competitors? The main competitors of Zimmer Biomet include Penumbra (PEN), Stryker (SYK), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Smith & Nephew SNATS (SNN), Solventum (SOLV), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), and Glaukos (GKOS). These companies are all part of the "medical" sector. Zimmer Biomet vs. Its Competitors Penumbra Stryker GE HealthCare Technologies Koninklijke Philips Smith & Nephew SNATS Solventum Stevanato Group iRhythm Technologies Bausch + Lomb Glaukos Zimmer Biomet (NYSE:ZBH) and Penumbra (NYSE:PEN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership. Is ZBH or PEN more profitable? Penumbra has a net margin of 11.54% compared to Zimmer Biomet's net margin of 10.51%. Zimmer Biomet's return on equity of 12.76% beat Penumbra's return on equity.Company Net Margins Return on Equity Return on Assets Zimmer Biomet10.51% 12.76% 7.21% Penumbra 11.54%11.55%8.76% Do insiders and institutionals hold more shares of ZBH or PEN? 88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 1.4% of Zimmer Biomet shares are owned by company insiders. Comparatively, 4.2% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts recommend ZBH or PEN? Zimmer Biomet presently has a consensus price target of $111.94, suggesting a potential upside of 12.57%. Penumbra has a consensus price target of $302.81, suggesting a potential upside of 19.83%. Given Penumbra's stronger consensus rating and higher possible upside, analysts plainly believe Penumbra is more favorable than Zimmer Biomet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zimmer Biomet 2 Sell rating(s) 8 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.45Penumbra 0 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.89 Does the media refer more to ZBH or PEN? In the previous week, Zimmer Biomet had 9 more articles in the media than Penumbra. MarketBeat recorded 20 mentions for Zimmer Biomet and 11 mentions for Penumbra. Zimmer Biomet's average media sentiment score of 0.89 beat Penumbra's score of 0.52 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 12 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ZBH or PEN? Zimmer Biomet has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Which has higher earnings & valuation, ZBH or PEN? Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZimmer Biomet$7.83B2.51$903.70M$4.1124.20Penumbra$1.19B8.25$14.01M$3.7667.21 SummaryZimmer Biomet and Penumbra tied by winning 8 of the 16 factors compared between the two stocks. Get Zimmer Biomet News Delivered to You Automatically Sign up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZBH vs. The Competition Export to ExcelMetricZimmer BiometMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$19.49B$10.68B$6.11B$21.91BDividend Yield1.01%1.91%5.73%3.62%P/E Ratio24.2020.5185.3630.12Price / Sales2.5126.68601.9667.12Price / Cash7.4625.0737.4624.26Price / Book1.593.4812.424.70Net Income$903.70M$208.83M$3.32B$1.01B7 Day Performance2.12%-0.59%0.57%0.49%1 Month Performance0.36%3.16%10.52%1.61%1 Year Performance-5.70%-6.35%72.99%13.30% Zimmer Biomet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZBHZimmer Biomet4.769 of 5 stars$99.44+1.1%$111.94+12.6%-4.9%$19.49B$7.83B24.2017,000Analyst ForecastPENPenumbra4.5133 of 5 stars$255.35-0.3%$302.93+18.6%+22.3%$9.96B$1.28B67.914,500Analyst ForecastSYKStryker4.9572 of 5 stars$365.99-1.2%$430.33+17.6%+3.0%$139.92B$22.60B48.4853,000Positive NewsAnalyst ForecastGEHCGE HealthCare Technologies4.0146 of 5 stars$76.41-0.2%$86.89+13.7%-19.3%$34.89B$19.97B15.6653,000Positive NewsAnalyst ForecastPHGKoninklijke Philips3.618 of 5 stars$28.04+0.1%N/A-13.4%$27.00B$17.86B147.5866,678SNNSmith & Nephew SNATS3.516 of 5 stars$35.94-1.0%$36.00+0.2%+24.1%$15.65B$5.81B16.6417,349Analyst ForecastSOLVSolventum2.88 of 5 stars$73.88-0.2%$84.60+14.5%+2.7%$12.81B$8.25B34.2022,000Positive NewsSTVNStevanato Group1.5013 of 5 stars€24.57-5.4%N/A+29.8%€7.44B€1.15B45.505,521IRTCiRhythm Technologies1.4907 of 5 stars$175.74+0.1%$172.17-2.0%+192.2%$5.65B$591.84M-59.982,000Analyst ForecastBLCOBausch + Lomb1.5837 of 5 stars$14.87-2.2%$15.60+4.9%-27.7%$5.26B$4.79B-19.0613,500GKOSGlaukos4.4265 of 5 stars$86.64-0.9%$122.00+40.8%-33.1%$4.97B$432.95M-52.51780Analyst Forecast Related Companies and Tools Related Companies Penumbra Competitors Stryker Competitors GE HealthCare Technologies Competitors Koninklijke Philips Competitors Smith & Nephew SNATS Competitors Solventum Competitors Stevanato Group Competitors iRhythm Technologies Competitors Bausch + Lomb Competitors Glaukos Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZBH) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zimmer Biomet Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zimmer Biomet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.